home libri books Fumetti ebook dvd top ten sconti 0 Carrello

Torna Indietro

 - new antibody formats

New Antibody Formats

Disponibilità: Normalmente disponibile in 20 giorni
A causa di problematiche nell'approvvigionamento legate alla Brexit sono possibili ritardi nelle consegne.

195,98 €
186,18 €

Questo prodotto usufruisce delle SPEDIZIONI GRATIS
selezionando l'opzione Corriere Veloce in fase di ordine.

Pagabile anche con 18App Bonus Cultura e Carta del Docente

Facebook Twitter Aggiungi commento

Spese Gratis


Lingua: Inglese
Pubblicazione: 06/2022

Note Editore

New Antibody Formats, Volume 369 in the International Review of Cell and Molecular Biology serial, highlights new advances in the field with this new volume presenting interesting chapters on a variety of important topics, including Current innovative engineered antibodies, Advances in bispecific antibodies, Applications of trimerbodies for cancer immunotherapy, Multispecific mAb-Anticalin formats, New antibody formats to treat Lung Cancer, Immunocytokines: from bench to bedside, and Single domain antibodies in cancer.

  • Provides the authority and expertise of leading contributors from an international board of authors
  • Presents the latest release in the International Review of Cell and Molecular Biology serials
  • Updated release includes the latest information on New Antibody Formats


. Current innovative engineered antibodies Jose Yelamos 2. Opportunities and challenges of bi-specific antibodies Aina Segués, Shuyu Huang, Alice Sijts, Pedro Berraondo and Dietmar M. Zaiss 3. Applications of trimerbodies in cancer immunotherapy Marta Compte, Laura Sanz and Luis Álvarez-Vallina 4. Anticalin®-based therapeutics: Expanding new frontiers in drug development Aizea Morales-Kastresana, Martin Siegemund, Stefan Haak, Janet Peper-Gabriel, Vanessa Neiens and Christine Rothe 5. Overcoming the limitations of cytokines to improve cancer therapy Claudia Augusta Di Trani, Assunta Cirella, Leire Arrizabalaga, Myriam Fernandez-Sendin, Angela Bella, Fernando Aranda, Ignacio Melero and Pedro Berraondo 6. Emerging applications of nanobodies in cancer therapy Robin Maximilian Awad, Fien Meeus, Hannelore Ceuppens, Thomas Ertveldt, Heleen Hanssens, Quentin Lecocq, Lukasz Mateusiak, Katty Zeven, Hana Valenta, Timo W.M. De Groof, Yannick De Vlaeminck, Ahmet Krasniqi, Kim De Veirman, Cleo Goyvaerts, Matthias D'Huyvetter, Sophie Hernot, Nick Devoogdt and Karine Breckpot


Clément Thomas is holding a group leader position at the Department of Oncology of the Luxembourg Institute of Health (LIH; Luxembourg City, Luxembourg). He received his PhD in Molecular and Cellular Biology in 2003 from Strasbourg University (France) in 2003. Since that moment, he has been interested in cell plasticity with a particular focus on actin cytoskeleton remodeling mechanisms. After more than ten years working with plant models, he joined the department of Oncology of LIH and established a group focused on the functions of the actin cytoskeleton in two central and complementary processes underlying cancer progression: invasion and immune evasion. Clément Thomas and his colleagues characterized a family of small, evolutionary-conserved, LIM domain-containing proteins (cysteine and glycine-rich proteins) that crosslink actin filaments into stable actin bundles and established the role of these proteins in promoting the formation and activity of invadopodia in breast cancer cells. Lately, Clément Thomas' group has initiated a pioneering study aimed at elucidating the role of the cancer cell's actin cytoskeleton during immune evasion.
Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome "La Sapienza . Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.

Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:
OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.

Altre Informazioni



Condizione: Nuovo
Collana: International Review of Cell and Molecular Biology
Dimensioni: 229 x 152 mm
Formato: Copertina rigida
Pagine Arabe: 212

Dicono di noi